US equities
|
NVDA
$238.90
▲+2.12%
SPCX
$171.09
▲+7.63%
MU
$1,063.96
▼-1.02%
TSLA
$378.73
▲+2.20%
WBD
$30.95
▲+0.03%
MSFT
$525.18
▲+1.48%
SNDK
$1,704.16
▼-0.92%
AAPL
$332.89
▼-0.24%
NVDA
$238.90
▲+2.12%
SPCX
$171.09
▲+7.63%
MU
$1,063.96
▼-1.02%
TSLA
$378.73
▲+2.20%
WBD
$30.95
▲+0.03%
MSFT
$525.18
▲+1.48%
SNDK
$1,704.16
▼-0.92%
AAPL
$332.89
▼-0.24%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Articles published by Spectrum Pharmaceuticals, Inc.
Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Spectrum Pharmaceuticals Stockholders Vote “FOR” Proposed Transaction with Assertio Holdings, Inc.
July 20, 2023
From
Spectrum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
SPPI
Spectrum Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement
May 17, 2023
From
Spectrum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
SPPI
Spectrum Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate Update
May 09, 2023
From
Spectrum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
SPPI
Spectrum Pharmaceuticals Reports Fourth Quarter 2022 and Full Year 2022 Financial Results and Corporate Update
March 22, 2023
From
Spectrum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
SPPI
Spectrum Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update
March 17, 2023
From
Spectrum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
SPPI
Spectrum Pharmaceuticals Receives Permanent J-Code for ROLVEDON™ (eflapegrastim-xnst) Injection (J1449) from U.S. Centers for Medicare & Medicaid Services
February 08, 2023
From
Spectrum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
SPPI
Spectrum Pharmaceuticals Provides Update on ROLVEDON™ (eflapegrastim-xnst) Injection and Announces Unaudited Fourth Quarter 2022 Financial Results
January 31, 2023
From
Spectrum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
SPPI
Spectrum Pharmaceuticals Announces Management Changes
January 04, 2023
From
Spectrum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
SPPI
Spectrum Pharmaceuticals Announces New Employment Inducement Grants for Commercial Staff
December 27, 2022
From
Spectrum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
SPPI
Spectrum Pharmaceuticals’ ROLVEDON™ (eflapegrastim-xnst) Injection Added to NCCN Supportive Care Guidelines in Oncology for Hematopoietic Growth Factors
December 06, 2022
From
Spectrum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
SPPI
Spectrum Pharmaceuticals Receives Complete Response Letter from U.S. Food and Drug Administration for Poziotinib; Reaffirms Focus on the Commercialization of ROLVEDON™ (eflapegrastim-xnst) injection
November 25, 2022
From
Spectrum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
SPPI
Spectrum Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 10, 2022
From
Spectrum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
SPPI
Spectrum Pharmaceuticals to Report Third Quarter 2022 Financial Results and Provide Corporate Update
November 03, 2022
From
Spectrum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
SPPI
Spectrum Pharmaceuticals Announces Commercial Availability of ROLVEDON™ (eflapegrastim-xnst) Injection
October 21, 2022
From
Spectrum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
SPPI
Spectrum Pharmaceuticals Announces Debt Financing Agreement with SLR Capital Partners with $30 Million Funded at Closing
September 23, 2022
From
Spectrum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
SPPI
Spectrum Pharmaceuticals Announces Data from Poster Presentation for Poziotinib in NSCLC Patients with G778_P780dup HER2 Exon 20 Mutations at ESMO Congress 2022
September 10, 2022
From
Spectrum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
SPPI
Spectrum Pharmaceuticals Receives FDA Approval for ROLVEDON™ (eflapegrastim-xnst) Injection
September 09, 2022
From
Spectrum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
SPPI
Spectrum Pharmaceuticals Announces Poster Presentation for Poziotinib in NSCLC Patients with G778_P780dup HER2 Exon 20 Mutations at the Upcoming ESMO Congress 2022
September 05, 2022
From
Spectrum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
SPPI
Spectrum Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 11, 2022
From
Spectrum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
SPPI
Spectrum Pharmaceuticals to Participate in Two Upcoming Investor Conferences
June 02, 2022
From
Spectrum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
SPPI
Spectrum Pharmaceuticals to Present Data at 2022 ASCO Highlighting the Potential Predictive Capabilities of ctDNA as a Biomarker for Poziotinib Treatment Response
May 26, 2022
From
Spectrum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
SPPI
Spectrum Pharmaceuticals to Participate in H.C. Wainwright Global Investment Conference
May 17, 2022
From
Spectrum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
SPPI
Spectrum Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 12, 2022
From
Spectrum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
SPPI
Spectrum Pharmaceuticals Appoints Nora E. Brennan as Chief Financial Officer
May 11, 2022
From
Spectrum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
SPPI
Spectrum Pharmaceuticals Announces FDA Acceptance of BLA Resubmission for Eflapegrastim
April 11, 2022
From
Spectrum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
SPPI
Spectrum Pharmaceuticals Announces Poster Presentation at the Upcoming AACR Annual Meeting
April 04, 2022
From
Spectrum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
SPPI
Spectrum Pharmaceuticals Reports Fourth Quarter 2021 and Full Year 2021 Financial Results and Corporate Update
March 17, 2022
From
Spectrum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
SPPI
Spectrum Pharmaceuticals Announces an Oral Poziotinib Presentation at the Upcoming ESMO TAT 2022 Virtual Meeting
February 28, 2022
From
Spectrum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
SPPI
Spectrum Pharmaceuticals Announces New Strategic Investment by Hanmi Pharmaceutical
January 04, 2022
From
Spectrum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
SPPI
Spectrum Pharmaceuticals Announces Changes to Management Team and Board of Directors
December 01, 2021
From
Spectrum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
SPPI
